New partnership launched to facilitate the development of new drugs for children across Europe * May 23-25, Berlin (Germany)
conect4children (c4c) is a large collaborative paediatric network that will facilitate the development of new drugs and other therapies for children in Europe.
In support of Janssen, CMAST is involved in this six-year project. The kick-off meeting, taking place from May 23rd to May 25th at Bayer AG in Berlin (Germany), brings together key stakeholders across academia and industry.
c4c aims to set up an infrastructure that optimises the delivery of clinical trials in children across Europe through:
- a single point of contact for all sponsors, sites and investigators;
- efficient implementation of trials - adopting consistent approaches, aligned quality standards and coordination of sites at national and international level;
- collaboration with specialist and national networks;
- high quality input to study design and preparation through rigorous strategic and operational feasibility assessment;
- the promotion of innovative trial design and quantitative science methods;
- an education and training platform to shape the future leaders of paediatric drug development;
- the development of sustainable support for all these activities.
The consortium is a collaboration between academic and private sectors including 33 academic and 10 industry partners from 20 European countries, more than 50 third parties and around 500 affiliated partners.
With a budget of about €140m (IMI2 support of €67m and industry partners’ in-kind contribution of €73m), c4c is one of the biggest initiatives funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement n º 777389. The Innovative Medicines Initiative 2 Joint Undertaking is Europe’s biggest Public Private Partnership and is funded jointly by the European Union's Horizon 2020 research and innovation programme and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
The project is coordinated and led by:
- Fondazione PENTA
- The University of Liverpool
- Janssen Pharmaceutica NV and
- Bayer AG.
At CMAST we are passionate about life sciences and healthcare. Our team of more than 90 industry experts is dedicated to assisting life sciences & pharma companies and universities & research institutes in the creation and development of innovative healthcare solutions.
For this project CMAST was involved in building the consortium, in preparing the full proposal and in the negotiation phase, and will be involved in the project management now that the project is in execution phase.
Want to know more about our expertise in Funding, Multi-stakeholder collaborations and Project & Portfolio Management?
Please do not hesitate to get in touch!
Disclaimer - This communication reflects the views of the c4c Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein